Litigation Details for Teva Pharmaceuticals International GmbH v. Aurobindo Pharma, Ltd. (D. Del. 2020)

Teva Pharmaceuticals International GmbH v. Aurobindo Pharma, Ltd. (D. Del. 2020)

Docket		Date Filed	2020-05-11
Court	District Court, D. Delaware	Date Terminated	2021-10-20
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To	Jennifer L. Hall
Patents	10,010,533; 10,052,385; 8,609,707; 9,034,908; 9,144,568; 9,265,831; 9,572,796; 9,572,797; 9,572,887; 9,579,384; 9,597,397; 9,597,398; 9,597,399
Link to Docket	External link to docket

Details for Teva Pharmaceuticals International GmbH v. Aurobindo Pharma, Ltd. (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-05-11				External link to document

Last updated: July 23, 2026

ecutive summary
Teva Pharmaceuticals International GmbH v. Aurobindo Pharma, Ltd. (1:20-cv-00632) is a U.S. Hatch-Waxman patent litigation targeting an Aurobindo generic to a Teva-listed brand drug. The case is filed in federal court and proceeds on standard Paragraph IV-style theories of noninfringement, invalidity, or unenforceability tied to one or more Orange Book-listed patents. The litigation record is the key driver for launch timing: any court determination (or settlement) can trigger statutory remedies including potential automatic stay lifting and damages exposure under 35 U.S.C. § 271(e)(4).

Note: No plaintiff/brand name, asserted patent numbers, case disposition, or settlement terms are provided in the prompt, so a complete, citation-grade litigation summary with patent-by-patent analysis cannot be produced.

What happens in Teva v. Aurobindo (1:20-cv-00632) Hatch-Waxman patent litigation?

A Paragraph IV case between a brand (or brand affiliate) and a generic challenger typically turns on four workstreams: the asserted patent claims, the generic product’s ANDA-described composition and process, the generic’s freedom-to-operate arguments (noninfringement and invalidity), and any litigation-specific carveouts (inequitable conduct, prosecution history estoppel, or carveouts for regulatory exclusivity).

What claims and defenses usually decide Teva-Aurobindo disputes

Featured snippet answer: Courts usually decide whether Aurobindo’s proposed ANDA product infringes the asserted Teva patents and whether those patents are invalid or unenforceable. If infringement is found and invalidity is rejected, the generic launch can be blocked by the remaining patent term; if the patents are invalid or not infringed, the generic can launch earlier (subject to other legal bars).

What procedural posture typically matters in 1:20-cv-00632

Key milestone events that change leverage:

• complaint and asserted patents being identified in the pleadings
• claim construction rulings (often decisive for claim scope)
• summary judgment on infringement/invalidity
• trial (rare for small estates; common where claim construction is stable but technical infringement is contested)
• final judgment and appeal
• settlement-triggered consent judgment or dismissal

Which patents did Teva assert against Aurobindo in 1:20-cv-00632?

A complete litigation analysis requires the asserted patent list (publication and/or U.S. patent numbers), the specific claim numbers, and whether the asserted patents are:

• drug substance (active ingredient composition)
• drug product (formulation, salt, polymorph, particle size, coating)
• method-of-use
• manufacturing method

Featured snippet answer: The litigation summary cannot be completed without the asserted patent numbers and claim lists from the case record.

How does court analysis typically evaluate infringement in Teva v. Aurobindo ANDA cases?

In Hatch-Waxman cases, infringement is assessed against the ANDA product as described in the application and any described manufacturing process. Courts also look for claim limitations that are technical and quantifiable.

Formulation and process infringement

Typical infringement variables:

• particle size distribution, polymorph or solid-state form
• excipient composition and ranges
• dissolution profile or bioequivalence-related parameters when claimed
• manufacturing conditions tied to method claims

Method-of-use infringement

Typical variables:

• dosing regimen
• patient population limitation
• specific therapeutic indication and dosing timing
• labeling-driven evidence

How is validity litigated in Teva v. Aurobindo (1:20-cv-00632)?

Featured snippet answer: Validity turns on whether the asserted claims are anticipated or obvious in view of the prior art (often framed through combinations of references), and whether the patent meets written description, enablement, and definiteness requirements.

Common validity routes

• 35 U.S.C. § 102 anticipation
• 35 U.S.C. § 103 obviousness (Graham factors plus KSR)
• § 112 (written description, enablement, indefiniteness)
• unenforceability (inequitable conduct) if pled

What prior art categories tend to dominate

• published applications with similar compositions or methods
• clinical trial disclosures that overlap dosing regimens
• patent family disclosures showing early conception and enabling work
• journal formulations describing polymorphs or processing

What is the Orange Book status of the Teva-listed patents at issue in 1:20-cv-00632?

Orange Book status usually determines:

• whether the ANDA qualifies for the Paragraph IV framework
• the statutory exclusivity landscape
• whether the asserted patents are composition, method-of-use, or formulation/product

Featured snippet answer: A complete Orange Book mapping cannot be produced from the prompt without the brand name and patent numbers.

When does Teva’s patent estate lose exclusivity against Aurobindo’s ANDA?

Launch timing depends on:

• earliest expiration of the asserted patents
• any granted extensions
• pediatric exclusivity
• patent term adjustments (PTA)
• regulatory exclusivities (if implicated)
• settlement terms that can effectively accelerate or delay entry

Featured snippet answer: A specific exclusivity and expiration timeline cannot be generated without the asserted patent numbers and their expiration dates.

Did Teva and Aurobindo settle, and what terms typically follow in 1:20-cv-00632?

When Hatch-Waxman cases settle, outcomes usually appear as:

• a consent judgment
• dismissal with prejudice
• a licensing agreement (rare in fully litigated Paragraph IV cases unless the patent estate is narrow)
• agreed entry date or “carveout” around non-infringing products

Featured snippet answer: Settlement details and entry date risks cannot be summarized without the dispositive docket entry or settlement document.

What generic entry risks exist for Aurobindo if Teva wins (or loses) 1:20-cv-00632?

Risk outcomes are binary but differ in timing and damages:

If Teva wins

• Aurobindo’s ANDA launch is blocked through the effective patent life (or through an injunction period).
• Exposure may include damages under § 271(e)(4) for infringement of the brand patents during the “artificial” infringement window if the generic was not finally adjudged not to infringe.

If Aurobindo wins

• Court invalidation or noninfringement clears entry earlier, subject to any other unexpired patents and exclusivities listed in the Orange Book.
• Aurobindo can launch once any statutory stays expire and no other legal barriers exist.

How strong is the patent estate implied by Teva v. Aurobindo?

Strength is judged by:

• how many patents are asserted (the broader the assertion set, the more difficult it is for the generic to clear)
• whether asserted patents cluster around formulation vs method-of-use (formulation estates are often narrower but technical)
• whether the court issues claim construction early that narrows disputes
• whether the patents have long remaining terms and PTA/pediatric extensions

Featured snippet answer: Patent strength cannot be measured without the asserted patent list and their claim themes.

What should litigation-driven commercialization teams extract from 1:20-cv-00632?

Even without patent specifics, teams typically extract:

• the “entry path” if Aurobindo prevails (which patents cleared)
• the “delay risk” if Teva prevails (which patents remain enforceable)
• settlement leverage indicators (dismissal timing often signals settlement rather than adjudication)

Featured snippet answer: Extracting actionable commercialization conclusions requires the asserted-patent matrix and docket outcome.

Key Takeaways

• Teva v. Aurobindo (1:20-cv-00632) is a U.S. Hatch-Waxman-style patent dispute where launch timing and damages hinge on infringement and validity outcomes for Orange Book-listed patents.
• A credible, patent-by-patent litigation summary cannot be completed from the provided input because the asserted patent numbers, brand drug identity, and docket disposition are not included.

FAQs

1. What is the typical statutory remedy in Hatch-Waxman cases like Teva v. Aurobindo?
2. How do claim construction rulings affect ANDA infringement analysis in Paragraph IV litigation?
3. What kinds of patents (composition, formulation, method-of-use) most often drive settlement?
4. How does an appellate reversal change generic launch timing after judgment?
5. What common docket events signal a settlement in Paragraph IV cases?

References

1. 35 U.S.C. § 271(e)(4).
2. 35 U.S.C. § 112.
3. 35 U.S.C. § 102.
4. 35 U.S.C. § 103.